Edinburgh Research Explorer

MS-SMART Trial: a multi-arm phase 2b randomised, double blind, parallel group, placebo-controlled clinical trial comparing the efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis [NCT01910259]

Research output: Contribution to journalMeeting abstract

Standard

MS-SMART Trial : a multi-arm phase 2b randomised, double blind, parallel group, placebo-controlled clinical trial comparing the efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis [NCT01910259]. / MS -SMART Investigators.

In: Multiple Sclerosis, Vol. 24, 12.10.2018, p. 986-987.

Research output: Contribution to journalMeeting abstract

Harvard

MS -SMART Investigators 2018, 'MS-SMART Trial: a multi-arm phase 2b randomised, double blind, parallel group, placebo-controlled clinical trial comparing the efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis [NCT01910259]', Multiple Sclerosis, vol. 24, pp. 986-987.

APA

MS -SMART Investigators (2018). MS-SMART Trial: a multi-arm phase 2b randomised, double blind, parallel group, placebo-controlled clinical trial comparing the efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis [NCT01910259]. Multiple Sclerosis, 24, 986-987.

Vancouver

MS -SMART Investigators. MS-SMART Trial: a multi-arm phase 2b randomised, double blind, parallel group, placebo-controlled clinical trial comparing the efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis [NCT01910259]. Multiple Sclerosis. 2018 Oct 12;24:986-987.

Author

MS -SMART Investigators. / MS-SMART Trial : a multi-arm phase 2b randomised, double blind, parallel group, placebo-controlled clinical trial comparing the efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis [NCT01910259]. In: Multiple Sclerosis. 2018 ; Vol. 24. pp. 986-987.